AQR's DELTA Strategy Is The Most Viewed Product On eVestment's Platform In 2019
AQR Capital Management's DELTA strategy was the most viewed hedge fund product on industry tracker eVestment's platform in 2019, taking a 0.66% share of all clicks by the institutional investors and their consultants which subscribe to eVestment's system. AQR also took fifth place for the year, with its Style Premia product receiving 0.42% of all views. Renaissance Technologies' Institutional Equities Fund came in second, with Man Group's AHL TargetRisk product coming in third, and Autonomy Capital's Master Fund fourth.
AQR was also the most viewed firm, with a 2.56% share of all views. Bridgewater Associates (2.02%) Man Group (1.57%), Renaissance Technologies (1.31%) and BlackRock (1.29%) rounded out the top five.
For December specifically, AQR was the most viewed firm, followed by Hudson Bay Capital, La Francaise Investment Solutions, Bridgewater and Marshall Wace, but Hudson Bay Capital's Hudson Bay Fund received the most sets of eyeballs at the individual product level, moving AQR's DELTA Strategy down to second place.
The rest of the top ten most viewed firms are:
And the top ten most viewed individual products were:
December also saw a first for our monthly eVestment review: Fundamental Long/Short equity was not the strategy with the most views. Last month, that honour belonged to Fund of Funds Multi-Strategy, with Corbin Capital Partners' Pinehurst Institutional Ltd product the most viewed product in that universe.
Hudson Bay Capital was also the biggest riser - defined as the largest increase in views vs. the previous 6 month moving average; at the firm level and the product level last month.
© The Sortino Group Ltd
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.